CELL-CAPS SA
ActiveLimited or Corporation721001 - Research and experimental development in the pharmaceutical industrybioalps.org/organizations/cell-caps-sa
Biotechnology (Cell Encapsulation)Patients with dysfunctional cells or organs, particularly type 1 diabetes patients.
CELL-CAPS SA is a Swiss AG registered in Genève, GE. Its registered activity falls under Research and experimental development in the pharmaceutical industry.
AI-enriched data· marks AI-enriched fields
AI Insight
Registry narrative generated from SHAB/SOGC facts.
Officers11Active Relations9Deleted Relations0SOGC Records9First Record22.10.2015Latest Activity14.10.2025BiotechDiabetes TreatmentCell EncapsulationGeneva StartupEPFL Spin-off
Registry Information
- Swiss UID
- CHE-339.211.704
- Legal Name
- CELL-CAPS SA
- Legal Form
- Limited
- Incorporated
- 22 Oct 2015
- Share Capital
- 100'000 actions de CHF 1, nominatives, liées selon statuts
- Canton
- GE
- Status
- Active
- Country
- Switzerland
Company Purpose
Translating…
NOGA Codes
(Industry classification)Research and experimental development in the pharmaceutical industry
NPROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES72Scientific research and development721Research and experimental development on natural sciences and engineering7210Research and experimental development on natural sciences and engineering721001
Industry Health
Registered Address
Place de Cornavin 3, 1201 Genève
1201, Genève, GE
Companies at this address
Enrich from integrations
Pull data from your connected providers and merge it with the registry.
Registry Pulse
Registry pulse is a Pro feature
Auditor
Has auditorCCCG SA
Since
Current Directors & Officers
From the web
Target Customers
Patients with dysfunctional cells or organs, particularly type 1 diabetes patients.
Sources (4)
Hydrogel developed at EPFL offers real promise in treating diabetes
actu.epfl.ch
Hydrogel developed at EPFL offers real promise in treating diabetes | news.myScience / news / news 2019
myscience.ch
Un hydrogel de l’EPFL pour faciliter le traitement du diabète | news.myScience / actualités / actualités 2019
myscience.ch
Notification announcement of the second extraordinary shareholders meeting in 2018 - Company News - 北京智立医学技术股份有限公司
en.sunnyms.com